DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Muse (Alprostadil) - Summary

 
 



MUSE SUMMARY

MUSE® (alprostadil) is a single-use, medicated transurethral system for the delivery of alprostadil to the male urethra. Alprostadil is suspended in polyethylene glycol 1450 (as excipient) and is formed into a medicated pellet (micro-suppository measuring 1.4 mm in diameter by 3 mm or 6 mm in length) that resides in the tip of a translucent hollow applicator. MUSE is administered by inserting the applicator stem into the urethra after urination. The pellet containing alprostadil is delivered by depressing the applicator button (see Figure 1). The components of the delivery system are constructed of medical grade polypropylene. Each MUSE system is packaged in an individual foil pouch.

MUSE is indicated for the treatment of erectile dysfunction. Studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with similarly administered placebo.


See all Muse indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Muse (Alprostadil)

The catch of the day: Fishing for research data at the Museum of Science
Source: Psychology / Psychiatry News From Medical News Today [2015.08.26]
A computer game was used to lure research subjects at the museumPeople of all ages recently lined up to do some fishing at the Museum of Science in Boston.

Prescription for medical students: A day at the art museum?
Source: Medical Students / Training News From Medical News Today [2015.07.29]
With the growing number of people with Alzheimer's disease, understanding their care is vital for doctors.

more news >>

Published Studies Related to Muse (Alprostadil)

Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial. [2013]
alprostadil infusion in patients with dAMD... CONCLUSION: A numerical treatment effect in favor of alprostadil was visible,

[Clinical effects of alprostadil injection on acute kidney injury after cardiac surgical procedures]. [2010.08.24]
OBJECTIVE: To explore the clinical effects of alprostadil injection on acute kidney injury (AKI) after cardiac surgical procedures by a prospective randomized controlled trial... CONCLUSION: On the basis of routine therapy, alprostadil injection may promote the recovery of renal function in AKI-patients after cardiac surgical procedures.

Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. [2010.06]
PURPOSE: To our knowledge we report the first large, randomized, prospective penile rehabilitation clinical trial to compare the effectiveness of nightly intraurethral alprostadil vs sildenafil citrate after nerve sparing prostatectomy... CONCLUSIONS: This is the first study to directly compare the ability of alprostadil and a phosphodiesterase-5 inhibitor to enhance penile recovery subsequent to bilateral nerve sparing radical prostatectomy. The use of nightly subtherapeutic intraurethral alprostadil is well tolerated after radical prostatectomy. The benefit to return of erectile function of nightly sildenafil citrate and subtherapeutic intraurethral alprostadil appears to be comparable within the first year of surgery. Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. [2009.02]
INTRODUCTION: Alprostadil is approved for treatment of male erectile dysfunction (ED) by injection or urethral insertion. Topical delivery of alprostadil offers an improved alternative. AIM: To evaluate the long-term safety and efficacy of topical alprostadil cream... CONCLUSIONS: Topical alprostadil cream was considered effective and safe by most patients and their partners, with most AEs limited to the application site. Dose adjustment to 300 mcg alprostadil facilitated the greatest improvement in erectile function in the majority of patients. A separate report will integrate patient data from the open-label extension and prior double-blind studies.

[Effects of alprostadil and ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass in pediatric patients with congenital heart diseases] [2008.11.11]
OBJECTIVE: To investigate the therapeutic effects of alprostadil (Lipo-PGE1) and Ulinastatin on inflammatory response and lung injury after cardiopulmonary bypass (CPB) in pediatric patients with congenital heart diseases... CONCLUSION: Decreasing the inflammatory response after CPB, alprostadil and ulinastatin used during CPB effectively reduce the pulmonary injury via inhibition of the neutrophil activation and cytokines release.

more studies >>

Clinical Trials Related to Muse (Alprostadil)

The Use of Prostaglandin E1 in Head and Neck Microsurgery [Recruiting]
Prostaglandin E1 (PGE1 )has been shown to have vasodilatation and anti-thrombosis effects, so it is used by some surgeons after microsurgery to keep the patency of the anastomosed small vessels. However, PGE 1 may also causes some complications, like pleural effusion or deep vein thrombosis. Therefore, it remains uncertain whether a routine use of PGE 1 after head and neck microsurgery is justified. We aim to test the hypothesis that PGE 1 increases postoperative vessel patency rate in patients undergoing head and neck microsurgery, with a comparable complication rate as the control group.

Protective Effect of Lipo-PGE1 on Myocardial Injury Following Percutaneous Coronary Intervention [Not yet recruiting]
we hypothesized that periprocedural treatment with intravenous lipo-PGE1 may reduce myocardial injury and improve clinical outcomes in patients undergoing PCI.

Prostaglandin E1 in Outpatients With Intermittent Claudication [Completed]
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with Intermittent Claudication.

Alprostadil in Maculopathy Study (AIMS) [Terminated]

Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV [Completed]
The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency and height of major amputations in patients suffering from PAOD stage IV.

more trials >>

Reports of Suspected Muse (Alprostadil) Side Effects

Drug Ineffective (4)Type 2 Diabetes Mellitus (3)Wrong Technique in Drug Usage Process (2)Penile Pain (2)Anaphylactic Reaction (2)Bladder Pain (2)Overdose (2)Urethral Pain (2)Pubic Pain (2)Urethral Haemorrhage (2)more >>


Page last updated: 2015-08-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015